ARCA biopharma has reported that its Phase IIb ASPEN-COVID-19 clinical trial of the small recombinant protein, rNAPc2 (AB201), will progress without amendments.

The development comes after the Data and Safety Monitoring Committee (DSMC) conducted a pre-specified interim assessment and recommended completion of the trial without any modifications to the study design.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

rNAPc2 is a selective tissue factor (TF) inhibitor and is claimed to possess anti-inflammatory, anti-coagulant and anti-viral properties. It is to be used as a treatment for hospitalised individuals with severe Covid-19,

The global multicentre, randomised Phase IIb trial is analysing two rNAPc2 dose schedules as against anti-coagulant, heparin, in nearly 160 Covid-infected subjects with high D-dimer levels.

The change in D-dimer level from baseline to day eight versus heparin is the primary goal of the trial.

Other goals of the trial include assessing safety, determining the appropriate dose regimen of rNAPc2 for a prospective Phase III trial and analysing various other clinical goals.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company plans to conclude enrolment by the end of this year and report topline trial data in the first quarter of next year.

ARCA biopharma president and CEO Dr Michael Bristow said: “Clearing the final interim analysis with no recommended changes in the Phase IIb clinical trial design is an important step in a clinical trial and in the development of rNAPc2 for prevention of Covid-19-associated coagulopathy.

“We look forward to sharing the top-line trial results in the first quarter of next year and reviewing the findings with the FDA.”

In July, ARCA biopharma obtained approval from the regulatory agencies in Argentina and Brazil to initiate enrolment in Phase IIb trial of rNAPc2.